Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 89-98

  Doe, Chris ^a   Bentley, Ross ^a   Behm, David J ^a   Lafferty, Robert ^a   Stavenger, Robert ^a   Jung, David ^b   Bamford, Mark ^a   Panchal, Terry ^a   Grygielko, Eugene ^a   Wright, Lois L ^b   Smith, Gary K ^b   Chen, Zunxuan ^a   Webb, Christine ^a   Khandekar, Sanjay ^b   Yi, Tracey ^b   Kirkpatrick, Robert ^b   Dul, Edward ^b   Jolivette, Larry ^a   Marino Jr , Joseph P ^a   Willette, Robert ^a   Lee, Dennis ^a   Hu, Erding ^a,b   more..

^a Centres of Excellence for Cardiovascular Urogenital Drug Discovery   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; [4 (7 [[ 3 AMINO 1 PYRROLIDINYL]CARBONYL] 1 ETHYL 1H IMIDAZOL[4,5 C]PYRIDIN 2 YL) 1,2,5 OXADIAZOL 4 AMINE]; [N (3 [[2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 1H IMIDAZOL[4,5 C]PYRIDIN 6 YL]OXY]PHENYL) 4 [[2 (4 MORPHOLINYL)ETHYL] OXY]BENZAMIDE]; FASUDIL; GSK 269962A; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN SERINE THREONINE KINASE; RECOMBINANT ENZYME; RECOMBINANT HUMAN RHO KINASE INHIBITOR 1; RHO KINASE INHIBITOR; SB 729743; SB 742548; SB 7720770 B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERTENSION; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; CELLS, CULTURED; CYTOKINES; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MALE; OXADIAZOLES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; VASODILATOR AGENTS;

EID: 33845888587     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.110635     Document Type: Article

References (39)

1. Aihara M, Dobashi K, Iizuka K, Nakazawa T, and Mori M (2003) Comparison of effects of Y-27632 and isoproterenol on release of cytokines from human peripheral T cells. Int Immunopharmacol 3:1619-1625.
2. Aihara M, Dobashi K, Iizuka K, Nakazawa T, and Mori M (2004) Effect of Y-27632 on release of cytokines from peripheral T cells in asthmatic patients and normal subjects. Int Immunopharmacol 4:557-561.
3. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, and Kaibuchi K (1997) Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science (Wash DC) 275:1308-1311.
4. Amano M, Fukata Y, and Kaibuchi K (2000) Regulation and functions of Rhoassociated kinase. Exp Cell Res 261:44-51.
5. Bao W, Hu E, Tao L, Boyce R, Mirabile R, Thudium DT, Ma XL, Willette RN, and Yue TL (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61:548-558.
6. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, and Douglas SA (2002) Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys- Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137:449-458.
7. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95-105.
8. Eto M, Kozai T, Cosentino F, Joch H, and Luscher TF (2002) Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105:1756-1759.
9. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, Takeya M, Yoshimura T, and Takeshita A (2001) Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38:100-104.
10. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, and Laping NJ (2005) Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 313:943-951.
11. Hippenstiel S, Schmeck B, Seybold J, Krull M, Eichel-Streiber C, and Suttorp N (2002) Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. Biochem Pharmacol 64:971-977.
12. Hu E and Lee D (2005) Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets 9:715-736.
13. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, et al. (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO (Eur Mol Biol Organ) J 15:1885-1893.
14. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, and Takeshita A (2003) Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 92:1337-1343.
15. Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, and Willette RN (2003) p38 MAPK inhibitors ameliorate target organ damage in hypertension: part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther 307:932-938.
16. Khandekar SS, Yi T, Dul E, Wright L, Smith G, Lee D, Hu E, and Kirkpatrick RB (2005) Expression, purification, and characterization of an enzymatically active truncated human Rho-kinase I (ROCK I) domain expressed in Sf-9 insect cells. Protein Pept Lett 13:413-420.
17. Lee DL, Webb RC, and Jin L (2004) Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension 44:796-799.
18. Leung T, Chen XQ, Manser E, and Lim L (1996) The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 16:5313-5327.
19. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, and Tedgui A (2003) Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 93:884-888.
20. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, and Takeshita A (2001) Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38:1307-1310.
21. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, and Kaibuchi K (1996) Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO (Eur Mol Biol Organ) J 15:2208-2216.
22. Moriki N, Ito M, Seko T, Kureishi Y, Okamoto R, Nakakuki T, Kongo M, Isaka N, Kaibuchi K, and Nakano T (2004) RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res 27:263-270.
23. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, and Takeshita A (2001) Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 15:1062-1064.
24. Pinto YM, Paul M, and Ganten D (1998) Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 39:77-88.
25. Riento K and Ridley AJ (2003) ROCKs: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446-456.
26. Rikitake Y and Liao JK (2005) ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther 3:441-451.
27. Sambrook J, Fritsch EF, and Maniatis T (1989) Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor, NY.
28. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, and Makino N (2003) Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 35:59-70.
29. Segain JP, Raingeard de la Bletiere D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP, and Loirand G (2003) Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 124:1180-1187.
30. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, and Nakano T (2003) Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 92:411-418.
31. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM, and Narumiya S (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168:941-953.
32. Shimokawa H (2002) Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39:319-327.
33. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83:1325-1358.
34. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo M, and Narumiya S (2003) Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 23:5043-5055.
35. Ueda H, Itoh H, Yamauchi J, Morishita R, Kaziro Y, Kato K, and Asano T (2000) G protein γγ subunits induce stress fiber formation and focal adhesion assembly in a Rho-dependent manner in HeLa cells. J Biol Chem 275:2098-2102.
36. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, et al. (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature (Lond) 389:990-994.
37. 2+ sensitization in erectile function. J Biol Chem 277:30614-30621.
38. Wibberley A, Chen Z, Hu E, Hieble JP, and Westfall TD (2003) Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 138:757-766.
39. Ying Z, Jin L, Dorrance AM, and Webb RC (2004) Increased expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens 17:981-985.